166 related articles for article (PubMed ID: 36499500)
1. Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio.
Mlugu EM; Minzi OM; Kamuhabwa AAR; Diczfalusy U; Aklillu E
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499500
[TBL] [Abstract][Full Text] [Related]
2. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms.
Oda A; Suzuki Y; Yoshijima C; Sato H; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Itoh H; Ohno K
Br J Clin Pharmacol; 2023 Dec; 89(12):3648-3658. PubMed ID: 37522799
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.
Oda A; Suzuki Y; Sato H; Koyama T; Nakatochi M; Momozawa Y; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Wakai K; Matsuo K; Itoh H; Ohno K
Clin Transl Sci; 2024 Mar; 17(3):e13768. PubMed ID: 38465776
[TBL] [Abstract][Full Text] [Related]
5. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
Diczfalusy U; Nylén H; Elander P; Bertilsson L
Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
[TBL] [Abstract][Full Text] [Related]
6. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L
Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941
[TBL] [Abstract][Full Text] [Related]
7. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
Hoshikawa K; Naito T; Akutsu S; Saotome M; Maekawa Y; Kawakami J
Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):353-363. PubMed ID: 31652395
[TBL] [Abstract][Full Text] [Related]
9. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
Penzak SR; Rojas-Fernandez C
J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
[TBL] [Abstract][Full Text] [Related]
10. Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.
Suzuki Y; Oda A; Negami J; Toyama D; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
J Lipid Res; 2022 Mar; 63(3):100184. PubMed ID: 35181316
[TBL] [Abstract][Full Text] [Related]
11. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.
Habtewold A; Amogne W; Makonnen E; Yimer G; Nylén H; Riedel KD; Aderaye G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Pharmacogenomics J; 2013 Dec; 13(6):484-9. PubMed ID: 23089673
[TBL] [Abstract][Full Text] [Related]
13. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.
Nylén H; Sergel S; Forsberg L; Lindemalm S; Bertilsson L; Wide K; Diczfalusy U
Eur J Clin Pharmacol; 2011 Jul; 67(7):715-22. PubMed ID: 21246351
[TBL] [Abstract][Full Text] [Related]
15. Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.
Suzuki Y; Itoh H; Fujioka T; Sato F; Kawasaki K; Sato Y; Sato Y; Ohno K; Mimata H; Kishino S
Drug Metab Dispos; 2014 Jan; 42(1):105-10. PubMed ID: 24135442
[TBL] [Abstract][Full Text] [Related]
16. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain.
Ishida T; Naito T; Sato H; Kawakami J
Drug Metab Pharmacokinet; 2016 Jun; 31(3):242-8. PubMed ID: 27236640
[TBL] [Abstract][Full Text] [Related]
18. No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.
Mannheimer B; Wagner H; Östenson CG; Diczfalusy U
PLoS One; 2015; 10(4):e0121984. PubMed ID: 25835492
[TBL] [Abstract][Full Text] [Related]
19. Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension.
Taguchi R; Naito T; Kubono N; Ogawa N; Itoh H; Kawakami J
Pregnancy Hypertens; 2019 Jul; 17():209-215. PubMed ID: 31487643
[TBL] [Abstract][Full Text] [Related]
20. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
Br J Pharmacol; 2021 Aug; 178(16):3294-3308. PubMed ID: 33155675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
